SiteOne Therapeutics
About
Approach
Pipeline
News
Publications & Presentations
Contact
About
/
Approach
/
Pipeline
/
News
/
Publications & Presentations
/
Contact
/
Innovative Solutions for Hypersensitivity Disorders
Press Releases
About
/
Approach
/
Pipeline
/
News
/
Publications & Presentations
/
Contact
/
SiteOne Therapeutics to Present Research Findings for Selective Small Molecule Nav1.7 Inhibitors at the 2018 World Congress on Pain
July 19, 2018
Acclaimed Scientists and Physicians Join the Scientific Advisory Board of SiteOne Therapeutics to Help Guide the Advancement of Novel Non-Opioid Pain Therapeutics
April 05, 2018
SiteOne Therapeutics Announces Abstract Presentation at the Association for Research in Vision and Opthamology
March 26, 2018
U.S. Department of Defense Awards Grant to SiteOne Therapeutics, Supporting Research and Development of Selective Small Molecule NaV1.7 Inhibitors as Acute and Chronic Pain Therapeutics
November 07, 2017
SiteOne Therapeutics Appoints Debra Odink, Ph.D., As Chief Development Officer as the Company Advances Novel Pain Drug Candidates
September 06, 2017
SiteOne Therapeutics Announces Research and Development Agreement With Amgen to Advance Portfolio of Highly Selective, Potent Inhibitors of Naᵥ1.7 for Acute and Chronic Pain
January 06, 2017
Remembering George Miljanich, Ph.D, Founder & Chief Science Officer
January 05, 2017
SiteOne Therapeutics Secures Investment from Bozeman-based Next Frontier Capital
July 15, 2015
SiteOne Therapeutics Completes $1.5M Initial Round of Equity Financing, Secures $1.4M NIH Grant
September 23, 2014